GLPwatch
[Nephrology : what's new in 2025].
Rev Med Suisse · 2026
Last updated 2026-05-28In 2025, new treatments for kidney disease include semaglutide, which helps prevent chronic kidney disease in people with type 2 diabetes, and retatrutide, which reduces a key kidney damage marker in those with diabetes and existing kidney disease. A higher dose of icodextrin did not improve survival or hospital stays in peritoneal dialysis patients but increased fluid removal. A dialysate with a moderate potassium level, combined with a potassium binder, may help stabilize potassium levels and reduce heart rhythm issues in hemodialysis patients.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2026 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Chronic Kidney Disease |
Abstract
Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzumab improves the renal response in patients with lupus nephropathy. A double dose of icodextrin did not reduce mortality, peritonitis, or hospitalization rates compared to standard peritoneal dialysis treatment, though it increased ultrafiltration. In patients on hemodialysis, using a dialysate with an intermediate potassium concentration combined with a potassium chelator appears to stabilize serum potassium levels and reduce the occurrence of arrhythmias. Xenotransplantation and ex vivo perfusion techniques are being perfected in the search for a solution to organ shortage.
Verbatim abstract via PubMed 41540866 ↗